Pathway of the Month
2 Results
- Pathway of the MonthOpen Archive
MicroRNA in Lung Cancer
Journal of Thoracic OncologyVol. 1Issue 9p929–931Published in issue: November, 2006- S Patrick Nana-Sinkam
- Mark W. Geraci
Cited in Scopus: 34In the last decade, researchers have identified a novel mode of gene regulation in the form of a family of small RNAs. In 1993, investigators first identified in C. elegans a small RNA, lin-4, which affected developmental timing by forming a duplex with the 3′UTR of another gene, lin-14, thus preventing lin-14 translation.1 The identification of lin-4 represented the first small RNA-regulating target mRNA expression. In 2000, investigators identified another small RNA let-7 that regulated the gene let-4; however, unlike lin-4, let-7 was conserved across among several species. - Gene or Pathway of the MonthOpen Archive
Prostacyclin in Lung Cancer
Journal of Thoracic OncologyVol. 1Issue 6p503–505Published in issue: July, 2006- Robert L. Keith
- Mark W. Geraci
Cited in Scopus: 9Prostacyclin is a naturally occurring eicosanoid that possesses anti-inflammatory and anti-metastatic properties and has a suppressive role in tumor growth.1 Prostacyclin synthase (PGIS) is the final committed enzymatic step in the pathway of PGI2 production, occurring at a branch point where substrate can be directed toward either PGI2, thromboxane A2 (TxA2), or prostaglandin E2 (PGE2) (Figure 1). Eicosanoid production and balance is proving pivotal in lung tumorigenesis.